8-K: Quanterix Reports Second Quarter 2024 Financial Results, Revenue Up 10.8%

Quanterix announced its second quarter 2024 financial results, highlighting a 10.8% increase in revenue year-over-year and progress in Alzheimer's disease diagnostics.

Summary

• Quanterix reported a revenue of $34.4 million for the second quarter of 2024, a 10.8% increase compared to $31.0 million in the same period last year.
• The company's GAAP gross margin was 58.3%, down from 61.7% in the prior year, while non-GAAP gross margin was 52.3%, compared to 56.4% in the prior year.
• Quanterix experienced a net loss of $9.5 million, which is an increase of $3.4 million compared to the same quarter last year.
• The company's net cash usage for the quarter was $5.1 million, and they ended the quarter with $299.5 million in cash, cash equivalents, marketable securities, and restricted cash.
• Quanterix has revised its 2024 revenue guidance to a range of $134 million to $138 million, down from the previous range of $139 million to $144 million, due to a constrained capital funding environment.
• The company expects 2024 cash usage to be at the higher end of its prior range of $25 million to $30 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is positive revenue growth and progress in Alzheimer's diagnostics, the decrease in gross margins, increased net loss, and reduced revenue guidance are concerning.

Positives

• The company experienced a 10.8% increase in revenue compared to the same quarter last year.
• Accelerator service revenue grew by 35% year-over-year, showing strong demand for their technology.
• Quanterix is making progress in Alzheimer's disease diagnostics with successful validation of a multi-marker approach.
• The company has established new partnerships to expand access to Alzheimer's disease diagnostic testing.
• The company has a strong cash position with $299.5 million in cash, cash equivalents, marketable securities, and restricted cash.

Negatives

• The company's GAAP gross margin decreased from 61.7% to 58.3% compared to the same quarter last year.
• Non-GAAP gross margin also decreased from 56.4% to 52.3% compared to the same quarter last year.
• The net loss increased by $3.4 million compared to the same quarter last year.
• The company revised its 2024 revenue guidance downward due to a constrained capital funding environment.
• The company anticipates 2024 cash usage to be at the higher end of its prior range.

Risks

• The company faces a constrained capital funding environment, which has led to a reduction in revenue guidance.
• The company's gross margins have decreased compared to the previous year.
• The company's net loss has increased compared to the previous year.
• The company's cash usage is expected to be at the higher end of its prior range.

Future Outlook

Quanterix expects to continue executing against its strategy, delivering new menu for research customers, innovating toward a new platform, and building the infrastructure for blood-based Alzheimer's diagnostics. The company has revised its 2024 revenue guidance to $134 million to $138 million and anticipates 2024 cash usage to be at the higher end of its prior range of $25 million to $30 million.

Management Comments

• Masoud Toloue, Chief Executive Officer of Quanterix, stated that the research business delivered strong performance in the second quarter, growing double digits.
• Masoud Toloue highlighted the 35% increase in Accelerator service revenue, noting that customers are able to access their technology without impacting their capital expenditure budgets.

Industry Context

The announcement reflects the ongoing demand for advanced biomarker detection technologies, particularly in areas like Alzheimer's disease. The partnerships with major hospital systems and a leading Chinese laboratory indicate a growing market for Quanterix's diagnostic solutions. The use of their technology in a successful phase 3 trial by Annexon Biosciences also highlights the value of their platform in drug development.

Comparison to Industry Standards

• Quanterix's revenue growth of 10.8% is a positive sign, but the decrease in gross margins is a concern compared to other diagnostics companies.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) are also focused on advanced diagnostics, but they have different revenue models and growth trajectories.
• The 35% growth in Accelerator service revenue is a strong indicator of demand for their technology, which is a key differentiator compared to companies that primarily sell instruments.
• The partnerships with major hospital systems are similar to strategies employed by other diagnostic companies to expand market reach.
• The validation of a multi-marker approach for Alzheimer's disease detection is a significant step, as many companies are working on similar diagnostic solutions, such as those from Roche and Biogen.

Stakeholder Impact

• Shareholders may be concerned about the reduced revenue guidance and increased net loss.
• Employees may be impacted by the company's financial performance and any potential cost-cutting measures.
• Customers may benefit from the company's continued innovation and expansion of diagnostic testing.
• Suppliers may be affected by any changes in the company's spending patterns.
• Creditors may be monitoring the company's cash usage and financial performance.

Next Steps

• The company will host a conference call on August 8, 2024, to discuss the results.
• The company will continue to execute against its strategy, delivering new menu for research customers, innovating toward a new platform, and building the infrastructure for blood-based Alzheimer's diagnostics.

Key Dates

Keywords

Quanterix, biomarker detection, Simoa technology, Alzheimer's disease, diagnostics, financial results, revenue, gross margin, net loss, research, accelerator services, partnerships